Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema

Andrés F. Lasave, David G. Zeballos, Wael M. El-Haig, Manuel Daz-Llopis, David Salom, J. Fernando Arevalo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report the short-term results of a single intravitreal injection of bevacizumab (IVB) versus a single intravitreal injection of triamcinolone acetonide (IVT) to treat refractory noninfectious uveitic cystoid macular edema (CME). Methods: Twenty-eight consecutive patients (36 eyes) were retrospectively included. Patients received either 2.5mg of IVB (16 eyes) or 4mg of IVT (20 eyes). Results: In the IVT group, baseline best-corrected visual acuity (BCVA) was logMAR 1.1±0.2, and improved to 0.7±0.3 (p<.001) at 6 months. In the IVB group, baseline BCVA was logMAR of 1.2±0.4 and improved to 0.8±0.4 at 6 months (p.=031). At 6 months, central macular thickness (CMT) in the IVT group improved from 454.8±238.9μm to 296±134.4μm (p<.0001). Conclusion: A single IVT injection improves BCVA and reduces CMT more effectively than IVB in refractory noninfectious uveitic CME at 6 months.

Original languageEnglish (US)
Pages (from-to)423-430
Number of pages8
JournalOcular Immunology and Inflammation
Volume17
Issue number6
DOIs
StatePublished - Dec 2009
Externally publishedYes

Keywords

  • Bevacizumab
  • Noninfectious uveitis
  • Single intravitreal injection
  • Triamcinolone acetonide
  • Uveitic cystoid macular edema

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint

Dive into the research topics of 'Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema'. Together they form a unique fingerprint.

Cite this